| |
Physiotherapy
|
Splint therapy
|
P-value and significance of difference
|
|---|
|
All patients:
|
|
TDC at LM [mean (SD), n]
|
−0.512 (0.339), 37
|
−0.575 (0.361), 35
|
0.446 NS†
|
|
Number of items contributing to TDC at LM [mean (SD), n]
|
14.2 (6.6), 37
|
15.7 (8.3), 35
|
0.407 NS†
|
|
Patients with STx:
|
|
TDC at LM [mean (SD), n]
|
−0.807 (0.127), 19
|
−0.820 (0.161), 21
|
0.808 NS‡
|
|
Number of items contributing to TDC at LM [mean (SD), n]
|
12.2 (5.9), 19
|
15.6 (9.2), 21
|
0.152 NS§
|
|
Patients with UTx:
|
|
TDC at LM [mean (SD), n]
|
−0.200 (0.161), 18
|
−0.208 (0.244), 14
|
0.906 NS‡
|
|
Number of items contributing to TDC at LM [mean (SD), n]
|
16.3 (6.8), 18
|
15.7 (7.0), 14
|
0.832 NS§
|
- TDC at LM, last measurement of treatment outcome in the long-term. STx and UTx, successful and unsuccessful treatment respectively. †Student’s t-test for unpaired observations. NS, non-significance. ‡one-way ANOVA for the factor TDC between the various patient groups with different therapies and treatment outcomes. The factor TDC was significant (p < 0.0001), indicating TDC-values which were smaller for patients with STx (more negative TDC-values indicating more improvement) than for patients with UTx. The Bonferroni’s multiple comparison tests were non-significant between both therapies, for STx and UTx respectively (p-values indicated). §one-way ANOVA for the factor number of items contributing to TDC at LM which was non-significant (p = 0.328)
